You are here :
Home
Healthcare
Payment Link for Sterlitech Corporation - Track etched Membrane Market & Pharmaceutical Filtration Market
Global Drug formulations Market Research Report
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
 |
Equine Encephalomyelitis Equine Encephalomyelitis and Strangles, Equine Influenza, |
Upcoming |
|
|
Strangles Strangles and Equine Encephalomyelitis, Equine... |
Upcoming |
|
|
Equine Influenza Equine Influenza and Equine Encephalomyelitis, Strangles, |
Upcoming |
|
|
Equine Rhinopneumonitis Equine Rhinopneumonitis and Equine Encephalomyelitis, |
Upcoming |
|
|
Vibriosis Vibriosis and Pasteurellosis, Furunculosis and |
Upcoming |
|
|
Pasteurellosis Pasteurellosis and Vibriosis, Furunculosis and |
Upcoming |
|
|
Furunculosis Furunculosis and Vibriosis, Pasteurellosis and |
Upcoming |
|
|
Lutienizing Hormone-Releasing Hormone (LHRH) Antagonists Lutienizing Hormone-Releasing Hormone (LHRH) Antagonists and Lutienizing Hormone-Releasing Hormone (LHRH) Analogs and |
Upcoming |
|
|
Lutienizing Hormone-Releasing Hormone (LHRH) Analogs Lutienizing Hormone-Releasing Hormone (LHRH) Analogs and Lutienizing Hormone-Releasing Hormone (LHRH) Antagonists and |
Upcoming |
|
|
Anti-Androgens Anti-Androgens and Lutienizing Hormone-Releasing Hormone (LHRH) Antagonists and |
Upcoming |
|
|
Phase III (Immunotherapy) Phase III (Immunotherapy) and Phase I (Immunotherapy) and |
Upcoming |
|
|
Phase III (Targeted Therapy) Phase III (Targeted Therapy) and Phase I (Targeted Therapy) and |
Upcoming |
|
|
Phase III (Hormonal Therapy) Phase III (Hormonal Therapy) and Phase I (Hormonal Therapy) and |
Upcoming |
|
|
North America Live attenuated vaccines The North American Live attenuated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $805 million in 2013 and expected to be $999 million by 2018 at a CAGR of 4.4%. Live attenuated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
European Live attenuated vaccines Market The European Live attenuated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $956 million in 2013 and expected to be $1253 million by 2018 at a CAGR of 5.6%. Live attenuated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Asian Live attenuated vaccines Market The Asian Live attenuated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $428 million in 2013 and expected to be $745 million by 2018 at a CAGR of 11.7%. Live attenuated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
North American Inactivated vaccines Market The North American Inactivated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $627 million in 2013 and expected to be $818 million by 2018 at a CAGR of 5.5%. Inactivated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
European Inactivated vaccines Market The European Inactivated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $744 million in 2013 and expected to be $1026 million by 2018 at a CAGR of 6.6%. European Inactivated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Asian Inactivated vaccines Market Research Report The Asian Inactivated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $333 million in 2013 and expected to be $610 million by 2018 at a CAGR of 12.9%. Asian Inactivated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
North American Sub-unit vaccines Market The North American Sub-unit Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $29 million in 2013 and expected to be $37 million by 2018 at a CAGR of 4.8%. North American Sub-unit Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
Drug formulations
